Nesiritide for Acute Heart Failure: The Landmark Trial That Proved a Natriuretic Peptide Could Treat Decompensated Hearts

This was a two-part study. The efficacy trial enrolled 127 patients with severe heart failure (pulmonary wedge pressure ≥18 mmHg, cardiac index ≤2.7 L/min/m²) who received Swan-Ganz catheters and were randomized double-blind to placebo or one of two nesiritide doses for six hours. The comparative trial enrolled 305 patients randomized to open-label nesiritide or standard IV heart failure therapy for up to seven days without requiring hemodynamic monitoring.

This was the pivotal New England Journal of Medicine trial that demonstrated nesiritide — a recombinant form of the body's own BNP peptide — could effectively treat acute decompensated heart failure. It was one of the first major demonstrations that a synthetic natriuretic peptide could be used therapeutically, turning a cardiac biomarker into a treatment. The trial led to FDA approval of nesiritide (brand name Natrecor) for acute heart failure.

Natriuretic peptides (ANP, BNP, CNP) are the heart's natural counter-regulatory system — they lower blood pressure, reduce fluid overload, and protect the heart. This trial proved the concept that you could give patients a synthetic version of their own cardiac peptide to treat heart failure. While nesiritide's clinical use later became controversial (concerns about kidney function and mortality emerged in subsequent studies), this trial remains a landmark in the history of peptide therapeutics and the broader story of turning biomarkers into drugs.

The efficacy trial was only six hours long, providing no long-term outcome data. The comparative trial was open-label, introducing potential bias. Neither trial assessed mortality as a primary endpoint. Subsequent larger trials (ASCEND-HF, 2011) would later show that nesiritide, while safe, did not reduce mortality or rehospitalization compared to placebo, tempering initial enthusiasm.